Most of What Patients Hear About Longevity Is Not Supported by Human Data
That is the uncomfortable starting point for any honest clinical conversation about anti-aging medicine. The longevity space has exploded — venture capital is pouring billions into senolytic drugs, NAD+ precursors, and hyperbaric oxygen protocols, while a growing class of "longevity clinics" offers patients interventions that have never been tested in a randomized controlled trial in humans. As a physician, I find myself in an increasingly common position: fielding questions from intelligent, motivated patients who have done their homework on PubMed but lack the clinical training to distinguish a promising mouse study from actionable medical advice.
The gap between longevity science and longevity medicine is vast. Closing it responsibly is one of the more important challenges facing clinicians today.
What the Evidence Actually Shows
The biology of aging has made genuine progress. A landmark 2019 review in Nature mapped the major pathways — mTOR signaling, cellular senescence, mitochondrial dysfunction, and loss of proteostasis — that drive age-related decline. These are real mechanisms, validated across species, and several have yielded drug targets now in early-phase human trials. Rapamycin analogs, senolytics like dasatinib plus quercetin, and caloric restriction mimetics are all being studied. The science is legitimate.
But "being studied" is not the same as "ready for your patients."
The most discussed longevity drug in clinical circles is metformin. A 2013 study in Nature Communications demonstrated that metformin improved both healthspan and lifespan in mice — extending median life by roughly 5.83%. The TAME trial (Targeting Aging with Metformin) has been in development for years, designed to test whether metformin delays the composite onset of cardiovascular disease, cancer, dementia, and mortality in non-diabetic older adults. As of early 2025, we still do not have definitive results from a large, randomized human trial. The observational data is suggestive — diabetic patients on metformin appear to have lower all-cause mortality than non-diabetic controls in some cohorts — but observational data carries well-known confounders.
When patients ask me directly whether metformin is effective for anti-aging, my answer is honest: possibly, but we do not yet have the human trial data to prescribe it with confidence for that indication. I explain the mechanism, acknowledge the mouse data, and tell them the TAME trial matters precisely because we cannot extrapolate rodent lifespan results to human outcomes without rigorous testing.
Autophagy, Fasting, and the Supplement Problem
Another area where patient enthusiasm has outpaced evidence is autophagy — the cellular recycling process that degrades damaged proteins and organelles. A thorough review in Nature Reviews Molecular Cell Biology established that autophagy dysfunction contributes to neurodegeneration, cancer, and metabolic disease, and that enhancing autophagy extends lifespan in model organisms. Intermittent fasting, caloric restriction, and exercise all upregulate autophagy. So do certain compounds like spermidine and resveratrol — in cell cultures and animal models.
The clinical translation problem is significant. We cannot easily measure autophagy flux in living humans. We do not have validated biomarkers to tell a patient whether their fasting protocol is actually increasing autophagy in a clinically meaningful way. And the supplement industry has seized on the term — marketing "autophagy-boosting" products with no human efficacy data and no FDA oversight of the claims.
In my own practice, I advise patients that the behaviors most consistently associated with longevity are unremarkable: regular moderate exercise (150-300 minutes per week of moderate aerobic activity), adequate sleep, a Mediterranean-pattern diet, maintaining social connections, and not smoking. These interventions have decades of epidemiological and interventional data behind them. They are free. And they are routinely ignored in favor of a $200-per-month supplement stack.
The Risks Physicians Must Name
The longevity medicine space carries real risks that clinicians have an obligation to articulate clearly.
First, off-label polypharmacy. Patients combining metformin, rapamycin, NAD+ precursors, and peptides are conducting uncontrolled experiments on themselves. Drug interactions in this context are poorly characterized. Rapamycin is an immunosuppressant — its long-term use in otherwise healthy individuals could increase infection risk and impair vaccine responses. I have seen patients present with concerning lab values after self-prescribing longevity protocols sourced from podcasts.
Second, opportunity cost. Patients spending thousands annually on unproven interventions may be neglecting evidence-based preventive care: colonoscopies, cardiovascular risk assessment, cancer screening. The psychological appeal of longevity medicine — the sense of proactive control over aging — can paradoxically distract from the preventive medicine that actually saves lives at a population level.
Third, the clinics themselves. The direct-to-consumer longevity clinic model often operates outside traditional accountability structures. Many are cash-pay, many do not coordinate with a patient's primary care physician, and many are led by practitioners whose training may not include geriatrics, endocrinology, or the specific organ systems they claim to be optimizing.
How Physicians Should Navigate This Space
I believe physicians have a responsibility to engage with longevity science rather than dismiss it. Patients will pursue these interventions regardless — the question is whether they do so with or without competent medical guidance.
My approach, informed by my training at Stanford and years in clinical practice, is straightforward. I stay current on the primary literature. I acknowledge what is promising. I am explicit about what remains unproven. And I anchor every conversation in the patient's actual risk profile — their family history, their labs, their functional status — rather than abstract theories about cellular senescence.
The current state of longevity research is genuinely exciting at the basic science level. We understand aging better than at any point in history. But the translation from bench to bedside is measured in decades, not news cycles. Physicians owe patients that honesty.
Longevity medicine will eventually produce validated, prescribable interventions. We are not there yet for most of them. The best thing a clinician can do today is help patients separate signal from noise — and ensure that the pursuit of a longer life does not compromise the quality of the one they are living now.
Frequently Asked Questions
What longevity treatments are currently supported by clinical evidence in humans?
The interventions with the strongest human evidence remain lifestyle-based: regular exercise (150+ minutes per week of moderate aerobic activity), Mediterranean-pattern diets, adequate sleep, and smoking cessation. Pharmacologic agents like metformin and rapamycin show promise in preclinical models but lack completed large-scale randomized human trials for longevity-specific indications. Physicians should be cautious about recommending off-label drugs until trials like TAME report results.
Is metformin effective for anti-aging in non-diabetic adults?
Metformin extended lifespan in mouse models by approximately 5.83% and shows favorable signals in human observational studies, but we do not yet have results from a definitive randomized trial in non-diabetic humans. The TAME trial is designed to answer this question. Until it does, prescribing metformin specifically for anti-aging requires acknowledging that the evidence base remains incomplete, even if the biological rationale is plausible.
What are the risks of combining multiple off-label longevity drugs?
Stacking agents like metformin, rapamycin, NAD+ precursors, and peptides creates an uncontrolled polypharmacy experiment with poorly characterized drug interactions. Rapamycin in particular is an immunosuppressant that may increase infection susceptibility and impair vaccine efficacy in healthy individuals. Patients pursuing these protocols should do so under physician supervision with regular lab monitoring, not based on podcast recommendations.
What is Dr. Sina Bari's approach to advising patients about longevity medicine?
Dr. Sina Bari, a Stanford-trained surgeon, anchors longevity conversations in each patient's specific risk profile — family history, lab work, and functional status — rather than abstract anti-aging theories. His approach prioritizes evidence-based preventive care first, engages honestly with promising research, and clearly distinguishes between what is proven and what remains experimental. He stays current on primary literature to provide informed guidance rather than dismissing patient interest in the field.
How can patients evaluate whether a longevity clinic is credible?
Patients should verify that the clinic's practitioners have relevant specialty training (geriatrics, endocrinology, or internal medicine), that the clinic coordinates care with existing providers, and that recommended interventions reference specific peer-reviewed studies rather than vague claims. Red flags include cash-only models with no insurance coordination, protocols sourced from a single proprietary "program," and reluctance to share the evidence basis for recommended treatments.